The diabetes space continues to innovate, and it doesn’t look like that’s stopping any time soon, with 2024 set to be another banner year. At the end of 2023, we compiled a list of the 10 biggest diabetes technology stories of the year. Some of those stories didn’t end in 2023, though, as a few […]
Tandem Diabetes Care
Tandem stock dips after hours on Q4 misses, 10% growth expected in 2024
Tandem Diabetes Care (Nasdaq:TNDM) shares took a hit after hours on fourth-quarter results that came up short of the consensus forecast. Shares of TNDM fell 8% at $20.74 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 0.2%. […]
Tandem Diabetes Care launches Mobi mini automated insulin patch pump
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it kicked off the U.S. commercial launch of its Mobi insulin patch pump. The San Diego-based company says Mobi, which is fully controllable from a mobile app, is the world’s smallest durable automated insulin delivery (AID) system. It received FDA clearance for people with diabetes ages six and […]
The top IVD and diabetes tech stories of 2023
Over the course of 2023, the medtech industry produced another impressive year of innovation, with news coming from a variety of spaces. Chiefly among those were diabetes technologies and in vitro diagnostics (IVDs). We saw regulatory nods, product launches, funds raised and mergers fall apart. Looking at those two spaces in particular, here are five […]
Abbott integrates FreeStyle Libre 2 Plus into Tandem’s automated insulin pump
Abbott (NYSE:ABT) and Tandem Diabetes Care (Nasdaq:TNDM) today announced the integration of FreeStyle Libre 2 Plus CGM into the t:slim X2 insulin pump. This marks the first automated insulin delivery system to integrate the newly available Abbott FreeStyle Libre 2 Plus sensor. The FDA cleared the updated Abbott continuous glucose monitor (CGM) for use with […]
The 10 biggest diabetes tech stories from 2023
It was another banner year for diabetes technology, with regulatory approvals, product launches and M&A all playing their part. Diabetes technology’s impressive 12 months marked a major trend across medtech as a whole, too. In 2022, the diabetes space saw plenty of progress from some of its biggest names and this past year proved no […]
Tandem Diabetes Care launches diabetes management platform for insulin pump users
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched Tandem Source, a diabetes management platform. The platform, for both insulin pump users and healthcare providers, brings together features of Tandem Diabetes Care’s legacy offerings. It combines t:connect, t:connect HCP and t:connect Portal with new, comprehensive data reporting in one central, scalable platform. All Tandem pump […]
Tandem Diabetes Care launches first automated insulin pump integrated with Dexcom G7 CGM
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched its updated t:slim X2 insulin pump software with the Dexcom (Nasdaq:DXCM) G7. Integration makes Tandem the first to offer automated insulin delivery with the latest-generation Dexcom continuous glucose monitor (CGM). The FDA cleared the next-generation Dexcom G7 in December 2022. By February of this year, the […]
Tandem stock sinks after hours on Q3 misses, lowered guidance
Tandem Diabetes Care (Nasdaq:TNDM) shares took a massive hit after hours today on third-quarter results that missed the consensus forecast. Shares of TNDM fell nearly 20% at $14.27 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day up 1.1%. The […]
Tandem Diabetes Care has positive artificial pancreas data
Data from a Tandem Diabetes Care (Nasdaq:TNDM) study demonstrated the benefits of its automated insulin delivery technology. Diabetes Technology & Therapeutics made data available from the Control-IQ Observational (CLIO) study. It’s the largest prospective study of the Control-IQ advanced hybrid closed-loop technology to date. Twelve-month results showed, among other results, lower adverse events for type […]
